The contract is a positive technology validation but has minimal near-term financial impact. Monitor progress toward Stage 3 and commercial trials for signs of broader adoption. The stock may see modest positive momentum on the news, but given historical underperformance of BHST following similar announcements, any pop could be short-lived.
Price Chart
Executive Summary
BioHarvest Sciences announced a $1.2 million Stage 2 CDMO contract for developing a rare fragrance compound using its Botanical Synthesis platform, following a successful Stage 1 in March 2026. The contract, from a UAE-based investment group, includes 20% ownership of developed compositions and a manufacturing royalty, with production targeted for H2 2027. While the contract validates the platform, the revenue impact is small relative to the $84M market cap and commercialization is years away.
Key Facts
- Signed $1.2M Stage 2 CDMO contract for rare fragrance development
- Stage 1 completed March 2026; Stage 2 expected to take 6-9 months
- BioHarvest retains 20% ownership of compositions and manufacturing royalty rights
- Commercial production targeted for second half of 2027
- Premium fragrance market estimated at $23B globally
Financial Impact
$1.2 million contract revenue with additional royalty potential, but near-term financial impact limited
Risk Factors
- No assurance of commercialization or achieving production timelines
- Single contract with undisclosed counterparty; limited diversification
- Long timeline to revenue (H2 2027) with execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001723464-26-000022 |
| Document: bhsc_ex991.htm | 0001723464-26-000022 |
| Document: 0001723464-26-000022-index-headers.html | 0001723464-26-000022 |
| Document: 0001723464-26-000022-index.html | 0001723464-26-000022 |
| Document: 0001723464-26-000022.txt | 0001723464-26-000022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.75 $1.67 | ▼ −4.18% | ▼ −4.64% | $1.68 (−3.72%) |
Oct 8, 2026 18d ago | 6-K | $1.50 $1.70 | ▲ +13.71% | ▲ +13.99% | $1.68 (+12.37%) |
Sep 15, 2026 5w ago | 6-K | $1.66 $1.46 | ▼ −12.05% | ▼ −14.61% | $1.68 (+1.20%) |
Sep 14, 2026 6w ago | 6-K | $1.78 $1.51 | ▼ −14.93% | ▼ −17.04% | $1.68 (−5.35%) |
Jul 15, 2026 14w ago | 6-K | $2.85 $2.18 | ▼ −23.51% | ▼ −22.53% | $1.68 (−41.05%) |
Jun 18, 2026 18w ago | 6-K | $3.26 $2.75 | ▼ −15.64% | ▼ −13.98% | $1.68 (−48.47%) |
May 28, 2026 21w ago | 6-K | $3.90 $3.56 | ▼ −8.72% | ▼ −8.67% | $1.68 (−56.92%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $1.68 (−59.62%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▲ +8.17% | ▲ +7.46% | $1.68 (+59.62%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $1.68 (−59.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers